Table 1 Demographic data and clinical characteristics of the study population (n = 125)
From: Chronic kidney disease-related atherosclerosis - proteomic studies of blood plasma
CKD1-2 | CKD 3-4 | CKD5 | CVD | HV | |
|---|---|---|---|---|---|
age [years] | 60.1 ± 8.01 | 59.9 ± 8.4 | 60.1 ± 10.1 | 59.4 ± 9.08 | 59.5 ± 11.2 |
males/females | 7/18 | 7/18 | 7/18 | 7/18 | 7/18 |
body mass index [kg/m2] | 28.19 ± 3.05 | 26.3 ± 2.01 | 24.7 ± 3.7 | 28.3 ± 3 | 24.6 ± 2.1 |
eGFR [ml/min/1.73m2] | 77.04 ± 22.9 | 20 ± 7.9 | 5.75 ± 7 | 92.7 ± 21.1 | 123.6 ± 17.6 |
arterial hypertension | 25 (100%) | 25 (100%) | 25 (100%) | 25 (100%) | 0 (0%) |
history of myocardial infarction/stroke | 4 (16%) | 5 (20%) | 14 (56%) | 17 (68%) | 0 (0%) |
statin treatment | 15 (60%) | 12 (48%) | 17 (68%) | 23 (92%) | 0 (0%) |
IACE treatment | 21 (84%) | 12 (48%) | 15 (60%) | 19 (76%) | 0 (0%) |
total cholesterol [mg/dL] | 217.06 ± 52.89 | 182.33 ± 29.69 | 179.53 ± 48.39 | 191.64 ± 41.22 | 188.73 ± 33.04 |
HDL cholesterol [mg/dL] | 56.2 ± 11.79 | 58.4 ± 7.64 | 46.89 ± 23.076 | 43.62 ± 10.16 | 70.62 ± 6.32 |
LDL cholesterol [mg/dL] | 168.66 ± 53.11 | 120.06 ± 17.11 | 105.97 ± 40.75 | 118.02 ± 31.66 | 93.96 ± 30.21 |
triglycerides [mg/dL] | 171.15 ± 70.1 | 116.66 ± 24.74 | 133.35 ± 50.83 | 149.96 ± 75.76 | 120.72 ± 37.11 |
alanine aminotransferase (ALT) [IU/L] | 22.51 ± 12.52 | 16.75 ± 9.96 | 16.01 ± 7.81 | 23.39 ± 18.9 | 15.23 ± 6.37 |
aspartate aminotransferase (AST) [IU/L] | 19.72 ± 14.11 | 16.35 ± 8.54 | 15.29 ± 5.61 | 18.8 ± 9.73 | 16.05 ± 7.56 |
bilirubin [mg/dL] | 0.59 ± 0.82 | 0.76 ± 0.17 | 0.53 ± 0.22 | 0.49 ± 0.18 | 0.67 ± 0.154 |
glucose [mg/dL] | 93.47 ± 9.52 | 91.85 ± 9.17 | 86.01 ± 10.51 | 92.28 ± 9.96 | 82.23 ± 12.19 |
high sensitivity C-reactive protein (hsCRP) [mg/L] | 0.62 ± 0.36 | 6.58 ± 4.05 | 12.32 ± 18.86 | 5.96 ± 2.68 | 1.29 ± 1.39 |
carotid artery intima media thickness (CA-IMT) [mm] | 0.72 ± 0.16 | 0.74 ± 0.11 | 0.77 ± 0.32 | 0.74 ± 0.19 | 0.48 ± 0.20 |